---
title: "Immuneering Corp. Reports Promising Cancer Trial Results"
description: "Immuneering Corp. (IMRX) reported promising results from its Phase 2a trial of IMM-1-104 for pancreatic cancer, showing encouraging response rates when combined with chemotherapy. The company also ann"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/232811961.md"
published_at: "2025-03-22T03:51:04.000Z"
---

# Immuneering Corp. Reports Promising Cancer Trial Results

> Immuneering Corp. (IMRX) reported promising results from its Phase 2a trial of IMM-1-104 for pancreatic cancer, showing encouraging response rates when combined with chemotherapy. The company also announced a collaboration with Regeneron Pharmaceuticals to evaluate IMM-1-104 with Libtayo for non-small cell lung cancer. Despite a net loss for 2024 due to increased R&D expenses, Immuneering has extended its cash runway into 2026, supporting future trials and data updates planned for 2025.

Immuneering Corp. Class A ( (IMRX) ) has released its Q4 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented to its investors.

Immuneering Corporation, a clinical-stage oncology company, is focused on developing therapies for cancer patients, with a lead product candidate, IMM-1-104, targeting RAS-driven tumors. In its latest earnings report, Immuneering shared promising updates from its Phase 2a trial of IMM-1-104, showing encouraging response rates in pancreatic cancer patients when combined with chemotherapy. The company also announced a collaboration with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo for non-small cell lung cancer. Financially, Immuneering reported a net loss for 2024, with increased research and development expenses attributed to its ongoing clinical trials. Despite the losses, the company has extended its cash runway into 2026, indicating a stable financial position to support its future plans. Looking ahead, Immuneering is preparing for additional trials and data updates in 2025, aiming to advance its pipeline and potentially offer improved treatment options for cancer patients.

## Trending Articles:

-   Paramount Stock (NASDAQ:PARA) Dips as it Pulls CBS Mornings out of Times Square
-   Ford Stock (NYSE:F) Notches Up With Ford Digital Experience Change
-   Intel Stock (NASDAQ:INTC) Gains on Work With “Mission-Critical Systems”

Questions or Comments about the article? Write to editor@tipranks.com

### Related Stocks

- [IMRX.US - Immuneering](https://longbridge.com/en/quote/IMRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data | Immuneering (IMRX) reported promising interim results from its Phase 2a trial of atebimetinib for pancreatic cancer, sho | [Link](https://longbridge.com/en/news/271839962.md) |
| Immuneering Insider Makes Bold New Bet on Company’s Future | Insider activity at Immuneering (IMRX) saw Director Peter Feinberg purchase 20,000 shares for $86,800, indicating confid | [Link](https://longbridge.com/en/news/272634480.md) |
| 11:03 ETNew Guidelines from NCCN Detail Fundamental Differences in Cancer in Children Compared to Adults | The National Comprehensive Cancer Network (NCCN) has released new Clinical Practice Guidelines for Pediatric Soft Tissue | [Link](https://longbridge.com/en/news/276145789.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |
| AgelessRx Expands Access to Multi-Cancer Early Detection Solutions, in Honor of Cancer Prevention Month | AgelessRx is expanding access to its multi-cancer early detection solutions in honor of Cancer Prevention Month. This in | [Link](https://longbridge.com/en/news/276180967.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
